Study of Argon Plasma Activated Liquid to Treat Helicobacter pylori Infection During Endoscopy Comparing Direct Stomach Treatment vs. Pre-Prepared Solution

What this Trial Is About

Helicobacter pylori H. pylori infection affects about half the worlds population and is a major cause of ulcers and gastric cancer. Current antibiotic treatments are effective in about 80% of cases, but increasing antibiotic resistance makes new treatments necessary. This study evaluates a new argon plasma-based therapy called HEAPE to reduce or eradicate H. pylori bacteria during endoscopic procedures, aiming to offer an alternative approach to antibiotic therapy. The study compares two ways of delivering plasma activated liquid PAL treatment HEAPE direct, where the stomach is filled with sodium chloride solution that is treated with argon plasma inside the stomach, and Pre-HEAPE, where the sodium chloride solution is treated outside the body and then administered into the stomach via endoscope. Both methods use the antibacterial properties of PAL without causing thermal damage to the stomach lining. After the procedure, patients receive standard antibiotic treatment and follow-up testing. Participants will undergo a urea breath test before and two hours after the PAL treatment to measure immediate changes in H. pylori levels and again four weeks later to assess eradication. Researchers will monitor symptoms, quality of life, and any side effects during and after the procedure. The study is randomized and designed to assess safety, tolerability, and proof of concept for PAL as a non-thermal antibacterial treatment for H. pylori infection.

H. Pylori Eradication With Argon Plasma During Endoscopy